Organovo Holdings, Inc. (ONVO): Price and Financial Metrics

Organovo Holdings, Inc. (ONVO): $1.03

0.02 (+1.98%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

ONVO Price/Volume Stats

Current price $1.03 52-week high $2.31
Prev. close $1.01 52-week low $0.89
Day low $1.01 Volume 43,800
Day high $1.05 Avg. volume 125,164
50-day MA $1.02 Dividend yield N/A
200-day MA $1.28 Market Cap 10.34M

ONVO Stock Price Chart Interactive Chart >

ONVO Stock Summary

  • ORGANOVO HOLDINGS INC's market capitalization of $10,339,401 is ahead of just 5.51% of US-listed equities.
  • With a price/sales ratio of 28.1, ORGANOVO HOLDINGS INC has a higher such ratio than 95.29% of stocks in our set.
  • Revenue growth over the past 12 months for ORGANOVO HOLDINGS INC comes in at -76.67%, a number that bests merely 2.36% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ORGANOVO HOLDINGS INC are LGVN, ASXC, WATT, LCTX, and AKTS.
  • ONVO's SEC filings can be seen here. And to visit ORGANOVO HOLDINGS INC's official web site, go to www.organovo.com.

ONVO Valuation Summary

  • ONVO's price/sales ratio is 26.6; this is 1109.09% higher than that of the median Healthcare stock.
  • ONVO's EV/EBIT ratio has moved up 75.5 over the prior 145 months.

Below are key valuation metrics over time for ONVO.

Stock Date P/S P/B P/E EV/EBIT
ONVO 2023-12-29 26.6 1.2 -0.5 -0.2
ONVO 2023-12-28 27.2 1.2 -0.5 -0.2
ONVO 2023-12-27 27.7 1.2 -0.5 -0.2
ONVO 2023-12-26 27.4 1.2 -0.5 -0.2
ONVO 2023-12-22 26.4 1.1 -0.5 -0.2
ONVO 2023-12-21 26.6 1.2 -0.5 -0.2

ONVO Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 58.51%.
  • The 5 year revenue growth rate now stands at -48.09%.
  • The 3 year price growth rate now stands at -81.41%.
Over the past 70 months, ONVO's revenue has gone down $2,522,000.

The table below shows ONVO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1.708 -9.216 -11.711
2022-09-30 1.577 -9.528 -11.947
2022-06-30 1.5 -9.454 -12.131
2022-03-31 1.5 -8.453 -11.448
2021-12-31 0 -9.026 -12.133
2021-09-30 0 -7.161 -11.144

ONVO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ONVO has a Quality Grade of D, ranking ahead of 17.68% of graded US stocks.
  • ONVO's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • SYRS, DRNA, and CPHI are the stocks whose asset turnover ratios are most correlated with ONVO.

The table below shows ONVO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -9.390
2021-03-31 0.000 NA -11.494
2020-12-31 0.000 NA -19.890
2020-09-30 0.011 0.956 -5936.667
2020-06-30 0.050 0.819 -9.301
2020-03-31 0.062 0.851 -4.771

Organovo Holdings, Inc. (ONVO) Company Bio


Organovo Holdings, Inc. focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company was founded in 2007 and is based in San Diego, California.


ONVO Latest News Stream


Event/Time News Detail
Loading, please wait...

ONVO Latest Social Stream


Loading social stream, please wait...

View Full ONVO Social Stream

Latest ONVO News From Around the Web

Below are the latest news stories about ORGANOVO HOLDINGS INC that investors may wish to consider to help them evaluate ONVO as an investment opportunity.

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024. The

Yahoo | December 6, 2023

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today ann

Yahoo | November 13, 2023

OVNO Continues Developing Breakthrough Treatments

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained

Yahoo | November 13, 2023

Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)

Organovo Holdings ( NASDAQ:ONVO ) Second Quarter 2024 Results Key Financial Results Net loss: US$3.99m (loss widened by...

Yahoo | November 11, 2023

Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The Company believes that the dat

Yahoo | November 8, 2023

Read More 'ONVO' Stories Here

ONVO Price Returns

1-mo 1.98%
3-mo -7.21%
6-mo -17.60%
1-year -52.09%
3-year -88.72%
5-year -94.81%
YTD -7.21%
2023 -21.28%
2022 -61.16%
2021 -70.49%
2020 72.90%
2019 -62.95%

Continue Researching ONVO

Here are a few links from around the web to help you further your research on Organovo Holdings Inc's stock as an investment opportunity:

Organovo Holdings Inc (ONVO) Stock Price | Nasdaq
Organovo Holdings Inc (ONVO) Stock Quote, History and News - Yahoo Finance
Organovo Holdings Inc (ONVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!